Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant · Source last updated 2026-01-22
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 30 days post-treatment, **up to 2 years**
What was measured
Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Groups in this outcome
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
Ixazomib Citrate: Given PO
Lenalidomide: Given PO
Dexamethasone: Given PO
Arm II (Lenalidomide)
Patients receive lenalidomide PO as in Arm I.
Lenalidomide: Given PO
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
20
Arm II (Lenalidomide)
22
Reported measurements
Abdominal pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Agitation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Alanine aminotransferase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Allergic reaction
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Allergic rhinitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Anemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
4
Not reported
Not reported
Not reported
Not reported
Anorexia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Anxiety
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Arthraigia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Aspartate aminotransferase increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Back Pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
5
Not reported
Not reported
Not reported
Not reported
Bloating
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Blurred vision
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Bronchospasm
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Bruising
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Buttock pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Chills
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Confusion
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Conspipation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
5
Not reported
Not reported
Not reported
Not reported
Cough
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
4
Not reported
Not reported
Not reported
Not reported
Dehydration
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Depression
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Diarrhea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
19
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
11
Not reported
Not reported
Not reported
Not reported
Dizziness
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
5
Not reported
Not reported
Not reported
Not reported
Dry eye
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Dry mouth
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Dysgeusia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Dyspepsia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Dyspnea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
4
Not reported
Not reported
Not reported
Not reported
Ear pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Edema Limbs
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Edema trunk
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Eye disorders - others
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Fall
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Fatigue
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
10
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
9
Not reported
Not reported
Not reported
Not reported
Fever
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Flu like symptoms
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
5
Not reported
Not reported
Not reported
Not reported
Flushing
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Fracture
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Gait disturbance
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Generalized muscle weakness
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Gum infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Headache
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Hypertension
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Hypokalemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Hypomagnesemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Hyponatremia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Hypotension
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Hypoxia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Immune system disorders
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Infections and infestations
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
INR increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Insomnia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Irritability
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Joint range of motion decreased cervical spine
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Lethargy
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Leukocytosis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Libido decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Localized edema
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Lung infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Lymphocyte count decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Memory impariment
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Metabolism and nutrition disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Mucosal infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Mucositis oral
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Muscle weakness lower limb
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Muscle weakness upper limb
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Myalgia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
4
Not reported
Not reported
Not reported
Not reported
Nasal congestion
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Nausea
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
10
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
4
Not reported
Not reported
Not reported
Not reported
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Neutrophil count decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
5
Not reported
Not reported
Not reported
Not reported
non-cardiac chest pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Oral dysesthesia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Oral pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Otitis externa
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
5
Not reported
Not reported
Not reported
Not reported
Pain in extremity
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Papulopustular rash
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Paresthesia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Paronychia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Peripheral motor neuropathy
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Peripheral sensory neuropathy
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
5
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
5
Not reported
Not reported
Not reported
Not reported
Platelet count decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Psychiatric disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Rash maculo-papular
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Renal and urinary disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Sepsis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Sinus bradycardia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Skin and subcutaneous tissue disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
skin hyperpigmentation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Small intestine infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Sore throat
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Spasticity
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Syncope
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Tinnitus
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Tooth infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Toothache
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Tremor
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
4
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Upper respiratory infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
7
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
6
Not reported
Not reported
Not reported
Not reported
Urinary frequency
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
3
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Urinary incontinence
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Urinary retention
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Urinary tract infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Vaginal discharge
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Vascular disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
Vomiting
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
6
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Weight gain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
2
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Wheezing
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
0
Not reported
Not reported
Not reported
Not reported
White blood cell decreased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Acute kidney injury
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Anal pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Bone pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Bronchial Infection
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Cardiac disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
chest pain -cardiac
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Conjunctivitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Creatinine Increased
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Cystitis noninfective
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Dry skin
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
External ear inflammation
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Flank pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Gastroesophageal reflux disease
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Gastrointestinal disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Gingival pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Hyperglycemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Hearing impaired
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Hemorrhoidal hemorrhage
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Hypocalcemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Hypophosphatemia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Musculoskeletal and connective tissue disorder - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
1
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Neck pain
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
3
Not reported
Not reported
Not reported
Not reported
Personality change
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Postnasal drip
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Pruritus
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Rash aceniform
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Respiratory, thoracic and mediastinal disorders - Other, specify
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
4
Not reported
Not reported
Not reported
Not reported
Sinus tachycardia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Sinusitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Somnolence
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Superficial thrombophlebitis
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Supraventricular tachycardia
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Thromboembolic event
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Vertigo
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
2
Not reported
Not reported
Not reported
Not reported
Weight loss
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
0
Not reported
Not reported
Not reported
Not reported
Arm II (Lenalidomide)
1
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
1
title
Abdominal pain
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
0
title
Agitation
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
2
title
Alanine aminotransferase increased
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
Allergic reaction
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
1
title
Allergic rhinitis
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
4
title
Anemia
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
Anorexia
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
0
title
Anxiety
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
3
title
Arthraigia
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
1
title
Aspartate aminotransferase increased
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
5
title
Back Pain
categories
measurements
group Id
OG000
value
3
group Id
OG001
value
2
title
Bloating
denoms
counts
group Id
OG000
value
20
group Id
OG001
value
22
units
Participants
description
Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
groups
description
Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only).
Ixazomib Citrate: Given PO
Lenalidomide: Given PO
Dexamethasone: Given PO
id
OG000
title
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
description
Patients receive lenalidomide PO as in Arm I.
Lenalidomide: Given PO
Triangle